Posner Marshall
Head and Neck Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, SW430, Boston, Massachusetts 02115, USA.
Oncologist. 2007 Aug;12(8):967-74. doi: 10.1634/theoncologist.12-8-967.
Despite continual advances in the treatment of head and neck cancer, disease-free survival, functional outcome, toxicity of therapy, and overall survival remain less than optimal. While traditional treatment has focused on surgical resection with or without radiation and chemoradiotherapy, newer combined-modality regimens may offer patients a better prognosis, organ preservation, and less morbidity. In this paper, single agents and doublet therapy are reviewed, as are emerging data on the utility of induction therapy, chemoradiotherapy, and surgery as a sequential treatment regimen. Disclosure of potential conflicts of interest is found at the end of this article.
尽管头颈部癌的治疗不断取得进展,但无病生存率、功能预后、治疗毒性和总生存率仍不尽人意。传统治疗主要集中在手术切除加或不加放疗以及放化疗,而新的联合治疗方案可能为患者提供更好的预后、器官保留和更低的发病率。本文回顾了单药治疗和双联疗法,以及诱导治疗、放化疗和手术作为序贯治疗方案的新兴数据。潜在利益冲突披露见本文末尾。